Straits Times Index
3,265.95 +1.42 (+0.04%) S&P 500
5,203.91 +16.24 (+0.31%) Dow
39,268.55 +212.16 (+0.54%) Nasdaq
16,329.71 +26.96 (+0.17%) Bitcoin USD
61,409.47 -1,130.35 (-1.81%) CMC Crypto 200
1,319.64 +19.55 (+1.50%)
Sagimet Biosciences Inc. (SGMT)
| Previous close | 4.4400 |
| Open | 4.4400 |
| Bid | 4.5200 x 200 |
| Ask | 4.6300 x 200 |
| Day's range | 4.3300 - 4.5900 |
| 52-week range | 2.1300 - 20.7100 |
| Volume | |
| Avg. volume | 827,993 |
| Market cap | 145.847M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.6600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 40.00 |
GlobeNewswireSagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced a General Session oral presentation of denifanstat Phase 2b FASCINATE-2 study data in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the European Association for the Study of the Liver (EASL)
- GlobeNewswire
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. “We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record
- GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024SAN MATEO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual investo
